Skip to main
SGMO
SGMO logo

Sangamo Therapeutics (SGMO) Stock Forecast & Price Target

Sangamo Therapeutics (SGMO) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Sangamo Therapeutics has received FDA agreement to leverage data from its Phase 1/2 STAAR trial to support an Accelerated Approval BLA filing for isa-vec, a gene therapy for symptomatic Fabry disease, which underscores the potential for favorable regulatory momentum. The trial results indicate significant improvements in renal function, illustrated by a positive mean annualized estimated glomerular filtration rate (eGFR) slope, while also demonstrating durable increases in α-Gal A activity and meaningful enhancements in patient-reported outcomes over extended treatment durations. Given the advancements in its Priority Neurology Pipeline and the promising data surrounding isa-vec and its safety profile, the outlook for Sangamo Therapeutics appears robust as the company approaches critical milestones in its development programs.

Bears say

Sangamo Therapeutics Inc is facing significant challenges in its financial performance, marked by a lack of successful product commercialization and prolonged timelines for clinical trials, which have led to increased operational losses. The company's reliance on a diverse but unproven pipeline of therapies in multiple therapeutic areas raises concerns about the viability and market potential of its developmental programs amidst intensifying competition in the genomic medicine sector. Additionally, the necessity for continuous capital raises to fund ongoing research and development could further dilute shareholder value, which reinforces a cautious outlook regarding the sustainability of its business model.

Sangamo Therapeutics (SGMO) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sangamo Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sangamo Therapeutics (SGMO) Forecast

Analysts have given Sangamo Therapeutics (SGMO) a Buy based on their latest research and market trends.

According to 6 analysts, Sangamo Therapeutics (SGMO) has a Buy consensus rating as of Oct 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sangamo Therapeutics (SGMO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.